Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a... The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine... SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production systems for protein and nucleic acid medicines, has been established as a... Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Introducing Primrose Bio: Enabling Innovative Therapeutic Discovery and Manufacturing
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m. The cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeutics
Advancing the manufacture of protein and nucleic acid-based biologic vaccines and therapeutics
BPI News: Primrose Bio Blossoms from Pelican and Primordial Genetics Merger